NASDAQ:ARCT - Arcturus Therapeutics Stock Price, Forecast & News

Arcturus Therapeutics trades on the NASDAQ under the ticker symbol "ARCT."

Arcturus Therapeutics Ltd (NASDAQ:ARCT) posted its quarterly earnings data on Monday, May, 13th. The biotechnology company reported ($0.68) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.53) by $0.15. The biotechnology company had revenue of $4.35 million for the quarter, compared to analysts' expectations of $3.47 million. Arcturus Therapeutics had a negative return on equity of 160.16% and a negative net margin of 63.05%. View Arcturus Therapeutics' Earnings History.

Arcturus Therapeutics is scheduled to release their next quarterly earnings announcement on Monday, March 16th 2020. View Earnings Estimates for Arcturus Therapeutics.

7 brokers have issued 1-year price targets for Arcturus Therapeutics' shares. Their forecasts range from $18.00 to $24.00. On average, they anticipate Arcturus Therapeutics' share price to reach $19.75 in the next twelve months. This suggests a possible upside of 42.7% from the stock's current price. View Analyst Price Targets for Arcturus Therapeutics.

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Arcturus Therapeutics in the last year. There are currently 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Arcturus Therapeutics.

Press coverage about ARCT stock has been trending somewhat positive this week, according to InfoTrie. The research firm scores the sentiment of press coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Arcturus Therapeutics earned a news sentiment score of 2.0 on InfoTrie's scale. They also gave headlines about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the company's share price in the near future. View News Stories for Arcturus Therapeutics.

Arcturus Therapeutics saw a drop in short interest during the month of January. As of January 31st, there was short interest totalling 157,500 shares, a drop of 14.0% from the January 15th total of 183,100 shares. Based on an average trading volume of 72,800 shares, the days-to-cover ratio is presently 2.2 days. Currently, 2.0% of the company's stock are short sold. View Arcturus Therapeutics' Current Options Chain.

Some companies that are related to Arcturus Therapeutics include Dova Pharmaceuticals (DOVA), ANI Pharmaceuticals (ANIP), CannTrust (CNTTF), DiaMedica Therapeutics (DMCAF), Aprea Therapeutics (APRE), Assembly Biosciences (ASMB), Axovant Sciences (AXON), Ardelyx (ARDX), Aptorum Group (APM), AnaptysBio (ANAB), Avedro (AVDR), Gemphire Therapeutics (GEMP), AMAG Pharmaceuticals (AMAG), Avadel Pharmaceuticals (AVDL) and Theratechnologies (THERF).

Based on aggregate information from My MarketBeat watchlists, some companies that other Arcturus Therapeutics investors own include Opko Health (OPK), Energy Transfer LP Unit (ET), KLA (KLAC), Corbus Pharmaceuticals (CRBP), Inovio Pharmaceuticals (INO), AbbVie (ABBV), Abeona Therapeutics (ABEO), Amicus Therapeutics (FOLD), Novavax (NVAX) and Viking Therapeutics (VKTX).

Arcturus Therapeutics' stock is owned by many different of retail and institutional investors. Top institutional investors include ARK Investment Management LLC (9.14%), Dfpg Investments LLC (3.01%), Nikko Asset Management Americas Inc. (1.85%), Sumitomo Mitsui Trust Holdings Inc. (1.85%), Credit Suisse AG (0.39%) and Bank of Montreal Can (0.37%). Company insiders that own Arcturus Therapeutics stock include Andy Sassine, Joseph E Payne, Magda Marquet and Peter C Farrell. View Institutional Ownership Trends for Arcturus Therapeutics.

ARCT stock was sold by a variety of institutional investors in the last quarter, including Sumitomo Mitsui Trust Holdings Inc., Nikko Asset Management Americas Inc., EAM Investors LLC, Renaissance Technologies LLC and Dfpg Investments LLC. View Insider Buying and Selling for Arcturus Therapeutics.

ARCT stock was purchased by a variety of institutional investors in the last quarter, including ARK Investment Management LLC, Credit Suisse AG, Bank of Montreal Can, Acadian Asset Management LLC, Goldman Sachs Group Inc. and Tower Research Capital LLC TRC . Company insiders that have bought Arcturus Therapeutics stock in the last two years include Andy Sassine, Joseph E Payne, Magda Marquet and Peter C Farrell. View Insider Buying and Selling for Arcturus Therapeutics.

Shares of ARCT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of ARCT stock can currently be purchased for approximately $13.84.

Arcturus Therapeutics has a market capitalization of $209.54 million and generates $15.75 million in revenue each year. The biotechnology company earns $-21,780,000.00 in net income (profit) each year or ($2.16) on an earnings per share basis. Arcturus Therapeutics employs 72 workers across the globe.View Additional Information About Arcturus Therapeutics.